NasdaqGS - Delayed Quote • USD
BioCryst Pharmaceuticals, Inc. (BCRX)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:37 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 11 | 11 | 11 | 10 |
Avg. Estimate | -0.21 | -0.16 | -0.63 | -0.35 |
Low Estimate | -0.28 | -0.32 | -0.84 | -0.76 |
High Estimate | -0.14 | -0.06 | -0.26 | -0.11 |
Year Ago EPS | -0.28 | -0.4 | -1.18 | -0.63 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 10 | 10 | 11 | 10 |
Avg. Estimate | 85.6M | 97.98M | 394.54M | 473.7M |
Low Estimate | 83.53M | 94.64M | 382.08M | 398M |
High Estimate | 87.41M | 101.53M | 403.01M | 510.06M |
Year Ago Sales | 68.78M | 82.49M | 331.41M | 394.54M |
Sales Growth (year/est) | 24.50% | 18.80% | 19.00% | 20.10% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.3 | -0.23 | -0.23 | -0.24 |
EPS Actual | -0.28 | -0.4 | -0.19 | -0.31 |
Difference | 0.02 | -0.17 | 0.04 | -0.07 |
Surprise % | 6.70% | -73.90% | 17.40% | -29.20% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.21 | -0.16 | -0.63 | -0.35 |
7 Days Ago | -0.21 | -0.16 | -0.62 | -0.34 |
30 Days Ago | -0.21 | -0.16 | -0.61 | -0.34 |
60 Days Ago | -0.22 | -0.16 | -0.64 | -0.35 |
90 Days Ago | -0.22 | -0.16 | -0.72 | -0.39 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 2 | 2 | 2 | 1 |
Growth Estimates
CURRENCY IN USD | BCRX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 25.00% | -- | -- | 5.40% |
Next Qtr. | 60.00% | -- | -- | 10.90% |
Current Year | 46.60% | -- | -- | 4.50% |
Next Year | 44.40% | -- | -- | 13.10% |
Next 5 Years (per annum) | 44.80% | -- | -- | 10.94% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Needham: Buy to Buy | 4/10/2024 |
Reiterates | Needham: Buy to Buy | 1/8/2024 |
Reiterates | Needham: Buy to Buy | 11/6/2023 |
Reiterates | RBC Capital: Outperform to Outperform | 9/25/2023 |
Upgrade | RBC Capital: Sector Perform to Outperform | 9/18/2023 |
Maintains | RBC Capital: Sector Perform to Sector Perform | 8/4/2023 |
Related Tickers
AUPH Aurinia Pharmaceuticals Inc.
4.9100
+0.82%
TGTX TG Therapeutics, Inc.
13.47
-3.16%
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
ACAD ACADIA Pharmaceuticals Inc.
16.71
+2.45%
QURE uniQure N.V.
4.5300
-0.22%
ARDX Ardelyx, Inc.
6.42
+1.74%
GRTS Gritstone bio, Inc.
0.8134
+6.40%
ABEO Abeona Therapeutics Inc.
3.2600
+2.19%
AKBA Akebia Therapeutics, Inc.
1.3400
+0.75%
FOLD Amicus Therapeutics, Inc.
10.28
+1.08%